<DOC>
	<DOCNO>NCT02818426</DOCNO>
	<brief_summary>UCPVAx therapeutic vaccine base telomerase-derived UCP design induce strong TH1 CD4 T cell response cancer patient . Three dos UCPVax ( 0,25 mg , 0,5 mg 1 mg ) test phase I/II study use Continuous Reassessment Method ( CRML ) dose escalation design model . The phase I dose escalation study design evaluate safety use UCPVax estimate Maximum Tolerated Dose ( MTD ) . The phase II dose deescalation design evaluate immunogenicity UCPVax accord dose level .</brief_summary>
	<brief_title>Universal Cancer Peptide-based Vaccination Metastatic NSCLC</brief_title>
	<detailed_description>UCPVax study prospective multicenter phase I/II study : 54 patient metastatic NSCLC enrol 5 center France . A translational research program perform good define eligibility criterion predictive biomarkers need randomized phase II Phase III trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent Histologically cytologically confirm NSCLC ( adenocarcinoma , squamous cell carcinoma , large cell carcinoma , undifferentiated carcinoma ) Stage IIIB amenable radiotherapy stage IV cancer accord TNM classification ( 7th edition ) recurrent NSCLC surgery amenable locoregional therapy . Pretreated least 2 3 line treatment ( include immunotherapy ) . Chemoradiation stage IIIB disease consider one treatment line . At least one measurable lesion CT scan MRI base RECIST criterion version 1.1 Performance status 0 1 ECOG scale Lifeexpectancy &gt; 3 month Adequate hematological , hepatic , renal function Prior history malignancy except : basal cell carcinoma skin , cervical intraepithelial neoplasia cancer curatively treat evidence disease least 5 year Symptomatic brain metastasis . Patients control brain metastasis radiation therapy asymptomatic brain metastasis may include . History active autoimmune disease ( lupus , rheumatoid arthritis , inflammatory bowel disease… ) Patients chronic treatment systemic corticoid immunosuppressive drug ( prednisone prednisolone ≤ 10 mg/day allow ) Positive serology Human Immunodeficiency Virus ( HIV ) Hepatitis C virus ( HCV ) ; presence serum antigens HBs Participation clinical study investigational product within 4 week prior start study treatment Pregnancy lactate patient . Patients medical psychiatric condition disease , Patients guardianship , curatorship protection justice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cancer immunotherapy</keyword>
	<keyword>CD4 T lymphocyte helper</keyword>
	<keyword>telomerase</keyword>
</DOC>